Literature DB >> 25588744

Sendai virus-mediated gene transfer of the c-myc suppressor far-upstream element-binding protein-interacting repressor suppresses head and neck cancer.

N Tanaka1, K Araki1, D Mizokami1, Y Miyagawa1, T Yamashita1, M Tomifuji1, Y Ueda2, M Inoue2, K Matsushita3, F Nomura3, H Shimada4, A Shiotani1.   

Abstract

Far-upstream element-binding protein-interacting repressor (FIR) is a transcription factor that inhibits c-Myc expression and has been shown to have antitumor effects in some malignancies. Here, we evaluated the antitumor effects of FIR using fusion gene-deleted Sendai virus (SeV/ΔF) as a nontransmissible vector against head and neck squamous cell carcinoma (HNSCC). Using in vitro and in vivo xenograft mouse models, we observed efficient expression of green fluorescent protein (GFP) following transduction with the SeV/ΔF vector encoding GFP (GFP-SeV/ΔF) into HNSCC cells. In vitro and in vivo studies revealed that administration of the FIR-encoded SeV/ΔF (FIR-SeV/ΔF) vector exerted significant antitumor effects, suppressed c-Myc expression and induced apoptosis in HNSCC. Additionally, the antitumor effects of FIR or the expression of GFP following administration of the FIR- or GFP-SeV/ΔF vector, respectively, were dependent on the multiplicity of infection or titer. Furthermore, the SeV/ΔF vector itself had no cytotoxic effects. Therefore, the SeV/ΔF vector may be safe and useful for the treatment of HNSCC, allowing for high-titer SeV/ΔF vector administration for anticancer gene therapy. In addition, SeV/ΔF vector-mediated FIR gene therapy demonstrated effective tumor suppression in HNSCC, suggesting that this therapy may have the potential for clinical use as a novel strategy for HNSCC treatment.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25588744     DOI: 10.1038/gt.2014.123

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  39 in total

1.  A far upstream element stimulates c-myc expression in undifferentiated leukemia cells.

Authors:  M I Avigan; B Strober; D Levens
Journal:  J Biol Chem       Date:  1990-10-25       Impact factor: 5.157

Review 2.  What real influence does the proto-oncogene c-myc have in OSCC behavior?

Authors:  Mario Pérez-Sayáns; José Manuel Suárez-Peñaranda; Gayoso-Diz Pilar; Francisco Barros-Angueira; José Manuel Gándara-Rey; Abel García-García
Journal:  Oral Oncol       Date:  2011-06-25       Impact factor: 5.337

3.  Sendai virus vector-mediated transgene expression in the cochlea in vivo.

Authors:  Sho Kanzaki; Akihiro Shiotani; Makoto Inoue; Mamoru Hasegawa; Kaoru Ogawa
Journal:  Audiol Neurootol       Date:  2006-12-06       Impact factor: 1.854

4.  Synergistic effect of non-transmissible Sendai virus vector encoding the c-myc suppressor FUSE-binding protein-interacting repressor plus cisplatin in the treatment of malignant pleural mesothelioma.

Authors:  Atsushi Kitamura; Kazuyuki Matsushita; Yuichi Takiguchi; Hideaki Shimada; Yuji Tada; Makako Yamanaka; Kenzo Hiroshima; Masatoshi Tagawa; Takeshi Tomonaga; Hisahiro Matsubara; Makoto Inoue; Mamoru Hasegawa; Yasunori Sato; David Levens; Koichiro Tatsumi; Fumio Nomura
Journal:  Cancer Sci       Date:  2011-05-09       Impact factor: 6.716

5.  SAP155-mediated splicing of FUSE-binding protein-interacting repressor serves as a molecular switch for c-myc gene expression.

Authors:  Kazuyuki Matsushita; Toshiko Kajiwara; Mai Tamura; Mamoru Satoh; Nobuko Tanaka; Takeshi Tomonaga; Hisahiro Matsubara; Hideaki Shimada; Rei Yoshimoto; Akihiro Ito; Shuji Kubo; Tohru Natsume; David Levens; Minoru Yoshida; Fumio Nomura
Journal:  Mol Cancer Res       Date:  2012-04-11       Impact factor: 5.852

Review 6.  The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy.

Authors:  Isabel M Chu; Ludger Hengst; Joyce M Slingerland
Journal:  Nat Rev Cancer       Date:  2008-04       Impact factor: 60.716

7.  Expression and maturation of Sendai virus vector-derived CFTR protein: functional and biochemical evidence using a GFP-CFTR fusion protein.

Authors:  H Ban; M Inoue; U Griesenbach; F Munkonge; M Chan; A Iida; E W F W Alton; M Hasegawa
Journal:  Gene Ther       Date:  2007-09-27       Impact factor: 5.250

8.  Postischemic administration of Sendai virus vector carrying neurotrophic factor genes prevents delayed neuronal death in gerbils.

Authors:  M Shirakura; M Inoue; S Fujikawa; K Washizawa; S Komaba; M Maeda; K Watabe; Y Yoshikawa; M Hasegawa
Journal:  Gene Ther       Date:  2004-05       Impact factor: 5.250

9.  Sendai virus transgene in a novel gene therapy for laryngotracheal disease.

Authors:  Daisuke Mizokami; Koji Araki; Nobuaki Tanaka; Hiroshi Suzuki; Masayuki Tomifuji; Taku Yamashita; Makoto Inoue; Mamoru Hasegawa; Akihiro Shiotani
Journal:  Laryngoscope       Date:  2013-05-10       Impact factor: 3.325

Review 10.  The current state of head and neck cancer gene therapy.

Authors:  Sufi Mary Thomas; Jennifer Rubin Grandis
Journal:  Hum Gene Ther       Date:  2009-12       Impact factor: 5.695

View more
  2 in total

Review 1.  Viral and Synthetic RNA Vector Technologies and Applications.

Authors:  Juliane W Schott; Michael Morgan; Melanie Galla; Axel Schambach
Journal:  Mol Ther       Date:  2016-07-05       Impact factor: 11.454

Review 2.  Single-cell genomic analysis of head and neck squamous cell carcinoma.

Authors:  Andres Stucky; Parish P Sedghizadeh; Susan Mahabady; Xuelian Chen; Cheng Zhang; Gang Zhang; Xi Zhang; Jiang F Zhong
Journal:  Oncotarget       Date:  2017-05-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.